Pasithea Therapeutics to Participate in EF Hutton Inaugural Global Conference
Pasithea Therapeutics to Participate in EF Hutton Inaugural Global Conference
PALO ALTO, Calif. and MIAMI, Fla., May 03, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea" or the "Company"), a biotechnology company focused on the discovery, research, and development of innovative treatments for Central Nervous System (CNS) disorders, today announced its CEO, Tiago Reis Marques, and its VP of Business Development, Mathew Lazarus will participate in the EF Hutton Global Conference, held in New York City, May 10-11, taking one-on-one meetings during Wednesday May 10, 2023.
加利福尼亞州帕洛阿爾託和佛羅裡達州邁阿密，2023年5月3日(環球通訊社)--帕西婭治療公司納斯達克：KTTA)(以下簡稱“帕西西亞”或“公司”)是一家專注於發現、研究和開發治療中樞神經系統疾病創新療法的生物技術公司。該公司今天宣佈，其首席執行官蒂亞戈·裡斯·馬奎斯和業務發展副總裁馬修·拉扎魯斯將參加5月10日至11日在紐約市舉行的EF Hutton全球會議，並於2023年5月10日(星期三)期間進行一對一的會談。
About the EF Hutton Global Conference
關於EF Hutton全球會議
The conference will feature senior executives from approximately 150 private and public companies from a wide variety of sectors, including Consumer & Retail, Energy & Infrastructure, Financial Services, Healthcare & Life Sciences, Industrials, Real Estate, Gaming & Lodging, Sustainability, and Technology, Media & Telecommunications. EF Hutton will be showcasing dynamic public and private companies across multiple sectors in an intimate conference setting, utilizing an impactful and productive one-on-one format. This comprehensive, two-day event provides company executives and investors the opportunity to interact with each other in a friendly, high-energy environment.
會議將有來自消費和零售、能源和基礎設施、金融服務、醫療保健和生命科學、工業、房地產、遊戲和住宿、可持續發展以及技術、媒體和電信等各行各業的約150傢俬營和上市公司的高級管理人員參加。EF Hutton將在一個親密的會議環境中展示多個行業的充滿活力的公共和私人公司，利用有影響力和富有成效的一對一形式。這一為期兩天的綜合性活動為公司高管和投資者提供了在友好、充滿活力的環境中相互交流的機會。
About Pasithea Therapeutics Corp.
Pasithea治療公司簡介
Pasithea Therapeutics is a biotechnology company primarily focused on the discovery, research and development of innovative treatments for central nervous system (CNS) disorders. With an experienced team of experts in the fields of neuroscience and psychopharmacology, Pasithea is developing new molecular entities for the treatment of neurological disorders, including Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS), Neurofibromatosis type 1 (NF1) and Noonan syndrome.
Pasithea Treateutics是一家生物技術公司，主要致力於發現、研究和開發治療中樞神經系統(CNS)疾病的創新療法。憑藉在神經科學和精神藥理學領域經驗豐富的專家團隊，Pasithea正在開發用於治療神經疾病的新分子實體，包括肌萎縮側索硬化症(ALS)和多發性硬化症(MS)、1型神經纖維瘤病(NF1)和努南綜合徵。
Forward Looking Statements
前瞻性陳述
This press release contains statements that constitute "forward-looking statements." Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company's filings with the U.S. Securities and Exchange Commission (SEC). Thus, actual results could be materially different. The Company undertakes no obligation to update these statements whether as a result of new information, future events or otherwise, after the date of this release, except as required by law.
本新聞稿包含構成“前瞻性陳述”的陳述。前瞻性陳述受許多條件的制約，其中許多條件不在公司的控制範圍之內。雖然公司相信這些前瞻性陳述是合理的，但不應過度依賴任何此類前瞻性陳述，這些前瞻性陳述是基於公司在本新聞稿發佈之日所掌握的資訊。這些前瞻性陳述是基於當前的估計和假設，會受到各種風險和不確定因素的影響，包括但不限於該公司提交給美國證券交易委員會(美國證券交易委員會)的檔案中陳述的風險和不確定因素。因此，實際結果可能會有很大不同。除法律要求外，本公司不承擔在本新聞稿發佈之日後因新資訊、未來事件或其他原因而更新這些陳述的義務。
Pasithea Therapeutics Corp. Company Contact
Dr. Tiago Reis Marques
Chief Executive Officer
Email: tiago@pasithea.com
Pasithea治療公司聯繫人
蒂亞戈·裡斯·馬奎斯博士
首席執行官
電子郵件：tiago@pasithea.com
Pasithea Therapeutics Corp. Investor Relations
Dan Schneiderman
Chief Financial Officer
Email: dschneiderman@pasithea.com
Pasithea治療公司投資者關係
丹·施奈德曼
首席財務官
電子郵件：郵箱：dschneiderman@pasithea.com
譯文內容由第三人軟體翻譯。